Pelegrin M, Marin M, Noël D, Piechaczyk M
Institute of Molecular Genetics of Montpellier, CNRS, France.
Hum Gene Ther. 1998 Oct 10;9(15):2165-75. doi: 10.1089/hum.1998.9.15-2165.
Our ability to produce and engineer human monoclonal antibodies provides a basis for the development of novel therapeutical strategies against a variety of diseases. These strategies not only include improved passive immunotherapy but also more sophisticated antibody-based gene therapies involving gene transfer approaches. Four of the major applications of antibody gene engineering in the field of gene therapy are reviewed here. These are (1) the redefinition of viral vector tropism of infection for better transduction of cells of therapeutical interest, (2) the grafting of new cell recognition activities to effector cells of the immune system to kill cancer and pathogen-infected cells, (3) the inhibition of cellular and viral functions through intracellular expression of antibody-derived molecules, and (4) the systemic delivery of therapeutic monoclonal antibodies by non-B cells in living organisms.
我们生产和改造人源单克隆抗体的能力为开发针对多种疾病的新型治疗策略奠定了基础。这些策略不仅包括改进的被动免疫疗法，还包括更复杂的基于抗体的基因疗法，涉及基因转移方法。本文综述了抗体基因工程在基因治疗领域的四个主要应用。它们分别是：（1）重新定义病毒载体的感染嗜性，以更好地转导具有治疗意义的细胞；（2）将新的细胞识别活性嫁接到免疫系统的效应细胞上，以杀死癌细胞和被病原体感染的细胞；（3）通过细胞内表达抗体衍生分子来抑制细胞和病毒功能；（4）在活生物体中由非B细胞进行治疗性单克隆抗体的全身递送。
